Currently, there are five anti‐PD‐1/PD‐L1 ICB immunotherapeutic drugs approved by the FDA for the treatment of bladder and other urothelial carcinomas (UCs), including three anti‐PD‐L1 and two anti‐PD‐1 antibodies 59 (Table 1). This evidence concerns the gene PDCD1 and urothelial carcinoma.